- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05972330
Efficacy of VRx MyBiotics Oral Lozenges
February 8, 2024 updated by: Viome
Testing the Efficacy of VRx MyBiotics Oral Lozenges to Improve the Oral Microbiome
This study will test the efficacy of Viome's VRx MyBiotics Oral Lozenges at improving the oral microbiome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a single arm, interventional trial on adults residing in the United States.
The study will test the efficacy of personalized oral biotic lozenges (VRx MyBiotics Oral Lozenges) at improving oral microbiome health according to Viome's Oral Health Score.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Momchilo Vuyisich
- Phone Number: (425) 300-6933
- Email: studies@viome.com
Study Contact Backup
- Name: Kaitlyn Sells
- Phone Number: (425) 300-6933
- Email: studies@viome.com
Study Locations
-
-
Washington
-
Bothell, Washington, United States, 98011
- Viome Life Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Any person with a US address that is 18 years old or older
- Able to speak and read English
- Willing and able to follow the trial instructions, as described in the recruitment letter
- Signed and dated informed consent prior to any trial-specific procedures.
Exclusion Criteria:
- Systemic antibiotic treatment 30 days prior to enrollment or during the trial
- Not willing to stop sporadic use (less frequently than daily) of any mouthwash.
- Significant diet, supplements, or lifestyle change in the previous 1 month or next 2 months once enrolled
- Allergy to tapioca, peppermint, or sweet potato
- Current diagnosis of periodontitis or other advanced oral disease (chronic recurrent caries, oral cancer, etc)
- No dental procedures 30 days prior to enrollment or during the trial (regular cleanings, bone grafts, dental implants, etc)
- Pregnancy or planned pregnancy
- Currently have cancer or undergoing cancer therapy
- Dentures
- Fewer than 20 teeth
- Use of at home teeth whitening products 30 days prior to enrollment or during the trial
- Start new medications or supplements during the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VRx MyBiotics Oral Lozenges
Participants will receive a 30 day supply of their personalized oral biotic lozenges.
|
VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viome Oral Health Score
Time Frame: ~ 4 months
|
Increase in oral health score as measured by Viome's Oral Health Score.
|
~ 4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Momchilo Vuyisich, Viome
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 26, 2023
Primary Completion (Actual)
January 26, 2024
Study Completion (Actual)
January 26, 2024
Study Registration Dates
First Submitted
July 24, 2023
First Submitted That Met QC Criteria
July 24, 2023
First Posted (Actual)
August 2, 2023
Study Record Updates
Last Update Posted (Actual)
February 12, 2024
Last Update Submitted That Met QC Criteria
February 8, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- V308
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Microbiome Health
-
University of California, DavisRenew Life Formulas IncCompleted
-
Fernanda Muñoz SepúlvedaSubvención Presidencial, Ministerio de Hacienda, Chile; Centro Interuniversitario... and other collaboratorsCompletedOral Health Knowledge | Oral Health Attitudes | Oral Health Self-efficacyChile
-
McGill UniversityLallemand Health SolutionsCompletedGut Microbiome | Skin Health | Carotenoid StatusCanada
-
University of Illinois at ChicagoCompletedWound Heal | Oral MicrobiomeUnited States
-
Academia Cearense de OdontologiaCompletedOral Health | Public Health | Diagnosis, OralBrazil
-
USDA, Western Human Nutrition Research CenterRecruitingGut Microbiome | Gut Health | Yogurt Intake | Gastrointestinal Immune FunctionUnited States
-
Medical University of ViennaActive, not recruitingOral Microbiome | Orthodontic Appliances, Fixed | Periodontal Index | Orthodontic Appliances, Removable | Cell CultureAustria
-
Designs for HealthRecruitingA Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental HealthOral HealthUnited States
Clinical Trials on VRx MyBiotics Oral Lozenges
-
Boston Medical CenterUniversity of Alabama at BirminghamNot yet recruitingLow-grade Oral DysplasiaUnited States
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.CytoPharm, Inc.Completed
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.Texas Tech University Health Sciences CenterTerminatedPulmonary Disease, Chronic Obstructive | Cough | Pulmonary FibrosisUnited States
-
University of AthensAlign Technology, Inc.RecruitingProbiotics | Halitosis | Orthodontic Appliance ComplicationGreece